Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

BLCO

Bausch + Lomb Corp

Feb 12 • 02:39PM ET

16.76

-0.27 -1.56 %

Healthcare • Medical Instruments & Supplies • Canada • NYSE

Peers: JNJ ALGN NVO TEVA PFE MRK CRL DHR ABT EXAS

| Held by: MGMT DFAX DFIC GUSA

Index	-	P/E	-	EPS (ttm)	-0.86	Insider Own	89.25%	Shs Outstand	354.09M	Perf Week	2.16%
Market Cap	5.94B	Forward P/E	20.82	EPS next Y	0.81	Insider Trans	0.00%	Shs Float	38.07M	Perf Month	-3.93%
Enterprise Value	10.63B	PEG	1.04	EPS next Q	0.36	Inst Own	10.20%	Short Float	8.83%	Perf Quarter	2.04%
Income	-305.00M	P/S	1.19	EPS this Y	-15.62%	Inst Trans	0.14%	Short Ratio	9.21	Perf Half Y	18.31%
Sales	4.98B	P/B	0.92	EPS next Y	51.47%	ROA	-2.23%	Short Interest	3.36M	Perf YTD	-1.84%
Book/sh	18.16	P/C	17.89	EPS next 5Y	20.07%	ROE	-4.69%	52W High	17.86 -6.13%	Perf Year	1.98%
Cash/sh	0.94	P/FCF	-	EPS past 3/5Y	- -	ROIC	-2.69%	52W Low	10.45 60.43%	Perf 3Y	0.93%
Dividend Est.	-	EV/EBITDA	18.64	Sales past 3/5Y	8.36% 4.87%	Gross Margin	54.02%	Volatility	2.89% 2.56%	Perf 5Y	-
Dividend TTM	-	EV/Sales	2.14	EPS Y/Y TTM	17.53%	Oper. Margin	2.85%	ATR (14)	0.45	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.98	Sales Y/Y TTM	6.23%	Profit Margin	-6.13%	RSI (14)	47.89	Recom	2.44
Dividend Gr. 3/5Y	- -	Current Ratio	1.51	EPS Q/Q	-799.12%	SMA20	-0.78%	Beta	0.60	Target Price	17.54
Payout	-	Debt/Eq	0.77	Sales Q/Q	7.11%	SMA50	-1.22%	Rel Volume	0.47	Prev Close	17.03
Employees	13500	LT Debt/Eq	0.77	Earnings	Feb 18 BMO	SMA200	14.15%	Avg Volume	365.33K	Price	16.76
IPO	May 06, 2022	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.85% 0.27%	Trades		Volume	137,106	Change	-1.56%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-26	Downgrade	Evercore ISI	Outperform → In-line	$18
Dec-11-25	Upgrade	Citigroup	Neutral → Buy	$20
Dec-02-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$21
Oct-01-25	Initiated	Goldman	Neutral	$16
May-02-25	Reiterated	H.C. Wainwright	Buy	$20 → $15
Mar-28-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$24 → $15
Dec-11-24	Downgrade	Citigroup	Buy → Neutral	$24 → $22
Dec-02-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$19
Oct-15-24	Upgrade	Evercore ISI	In-line → Outperform	$19 → $25
Jul-10-24	Initiated	Raymond James	Outperform	$19
May-06-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$16 → $18
Jan-04-24	Downgrade	Evercore ISI	Outperform → In-line	$19 → $17
Dec-12-23	Initiated	Stifel	Hold	$16
Oct-03-23	Resumed	Evercore ISI	Outperform	$20
May-30-23	Resumed	Morgan Stanley	Equal-Weight	$20
Mar-09-23	Initiated	Needham	Hold
Dec-21-22	Initiated	Barclays	Equal Weight	$17
Sep-12-22	Initiated	H.C. Wainwright	Buy	$21
Jul-26-22	Initiated	RBC Capital Mkts	Outperform	$22
Jun-24-22	Initiated	Evercore ISI	Outperform	$21

Show Previous Ratings

Today 08:50AM	Organon (OGN) Misses Q4 Earnings and Revenue Estimates (Zacks)
Feb-11-26 09:30AM	Bausch + Lomb CEO: Standing still is the new falling behind (Fortune)
Feb-09-26 11:02PM	3 Reasons to Sell BLCO and 1 Stock to Buy Instead (StockStory)
11:40AM	BLCO or DHR: Which Is the Better Value Stock Right Now? (Zacks)
Jan-29-26 11:34PM	1 Healthcare Stock to Research Further and 2 Facing Headwinds (StockStory)
11:40AM	Loading…
Jan-23-26 11:40AM	BLCO vs. HQY: Which Stock Is the Better Value Option? (Zacks)
Jan-20-26 07:15AM	Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18 (Business Wire)
Jan-05-26 07:00AM	Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S. (Business Wire)
Jan-02-26 04:30PM	Bausch + Lomb Completes Refinancing of Outstanding Term B Loans (Business Wire)
Dec-23-25 07:30AM	Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-17-25 04:30PM	Bausch + Lomb Announces Two Board of Directors Appointments (Business Wire)
Dec-12-25 04:48PM	Bausch + Lomb Announces Refinancing of Outstanding Term B Loans (Business Wire)
Dec-11-25 11:41AM	Why Bausch + Lomb (BLCO) Stock Is Trading Up Today (StockStory)
Dec-04-25 10:09PM	Wall Street Cautious on ?Bausch + Lomb Corporation (BLCO), Here's Why (Insider Monkey)
Dec-02-25 11:10AM	Why Bausch + Lomb (BLCO) Stock Is Up Today (StockStory)
04:30PM	Loading…
Nov-18-25 04:30PM	Bausch + Lomb to Participate in Citi Global Healthcare Conference (Business Wire)
Nov-13-25 02:57PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research) -5.48%
08:55AM	NYSE Content Advisory: Pre-Market Update + TKO and Polymarket Announce Partnership (PR Newswire)
08:41AM	Bausch + Lomb CEO Brent Saunders on growth outlook: Biggest contributor will be in surgical (CNBC TV)
Nov-10-25 06:59AM	Bausch + Lomb Reports More Than 690,000 Pounds of Contacts Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE Recycling Program (Business Wire)
04:28AM	Medical Devices & Supplies - Specialty Stocks Q3 In Review: Bausch + Lomb (NYSE:BLCO) Vs Peers (StockStory)
Nov-05-25 12:35AM	5 Revealing Analyst Questions From Bausch + Lomb's Q3 Earnings Call (StockStory)
Nov-03-25 04:30PM	Bausch + Lomb to Hold Investor Day on Nov. 13 (Business Wire)
Oct-30-25 01:34AM	BLCO Q3 Deep Dive: Pharmaceuticals and Pipeline Drive Growth, Margin Initiatives Take Shape (StockStory)
Oct-29-25 03:47PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research)
09:30AM	Bausch + Lomb (BLCO) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:05AM	Bausch + Lomb (BLCO) Q3 Earnings Beat Estimates (Zacks)
07:23AM	Bausch + Lomb (NYSE:BLCO) Reports Q3 In Line With Expectations, Stock Soars (StockStory)
07:06AM	Bausch + Lomb: Q3 Earnings Snapshot (Associated Press Finance)
06:58AM	Bausch + Lomb Announces Third-Quarter 2025 Results (Business Wire)
09:26AM	Loading…
Oct-28-25 09:26AM	Bausch & Lomb Corp (TSX:BLCO) Q3 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-27-25 11:12PM	Bausch + Lomb (BLCO) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Oct-20-25 06:44PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research)
11:36AM	Bausch + Lomb (BLCO) Stock Is Up, What You Need To Know (StockStory)
09:34AM	Stocks to Watch Monday: Amazon, Zions Bancorp, Kering (The Wall Street Journal)
07:41AM	Cooper Cos. Stock Rises as Report Says Activist Investor Takes Stake (Barrons.com)
07:25AM	Activist Jana Pushes Big Contact-Lens Combination of Cooper and Bausch + Lomb (The Wall Street Journal)
Oct-19-25 08:00PM	Activist Jana Takes Stake in Cooper, a Maker of Medical Devices (The Wall Street Journal)
Oct-17-25 12:24PM	3 Stocks Under $50 We Steer Clear Of (StockStory)
Oct-10-25 06:44PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research)
Oct-02-25 11:40AM	BLCO vs. DHR: Which Stock Should Value Investors Buy Now? (Zacks)
Oct-01-25 11:01AM	Goldman Sachs initiates ophthalmology coverage: Buy Glaukos, sell Cooper (Investing.com)
Sep-25-25 01:06PM	Bausch + Lomb, Enovis, and Haemonetics Shares Plummet, What You Need To Know (StockStory)
Sep-11-25 07:00AM	Bausch + Lomb Announces Publication of enVista Envy Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial (Business Wire)
Sep-09-25 07:00AM	Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA in Alleviating Discomfort in Symptomatic Contact Lens Wearers (Business Wire)
Sep-08-25 06:56PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research)
04:30PM	Bausch + Lomb (BLCO) Stock Trades Up, Here Is Why (StockStory)
07:00AM	Bausch + Lomb Launches ASANA Gas Permeable Lenses in the United States (Business Wire)
Sep-05-25 12:41AM	3 Healthcare Stocks Walking a Fine Line (StockStory)
Aug-22-25 02:25PM	Bausch + Lomb (BLCO) Stock Is Up, What You Need To Know (StockStory)
Aug-20-25 11:31PM	Medical Devices & Supplies - Specialty Stocks Q2 Highlights: Bausch + Lomb (NYSE:BLCO) (StockStory)
Aug-18-25 05:48PM	Icahn representations resign Bausch + Lomb board after agreement termination (Reuters)
05:01PM	Bausch + Lomb Announces Board Changes (Business Wire)
Aug-14-25 07:15AM	Bausch + Lomb to Participate in Upcoming Investor Conferences (Business Wire)
Aug-12-25 11:55PM	5 Revealing Analyst Questions From Bausch + Lomb's Q2 Earnings Call (StockStory)
11:48PM	BLCO Q2 Deep Dive: Product Launches Offset Margin Pressures, Management Highlights Pipeline Investments (StockStory)
Aug-07-25 12:38AM	1 Stock Under $50 to Target This Week and 2 We Ignore (StockStory)
Jul-30-25 03:05PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research) -6.42%
12:16PM	Why Bausch + Lomb (BLCO) Stock Is Down Today (StockStory)
09:30AM	Bausch + Lomb (BLCO) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
08:10AM	Bausch + Lomb (BLCO) Q2 Earnings and Revenues Surpass Estimates (Zacks)
07:34AM	Bausch + Lomb's (NYSE:BLCO) Q2 Sales Top Estimates, Full-Year Outlook Slightly Exceeds Expectations (StockStory)
07:04AM	Bausch + Lomb: Q2 Earnings Snapshot (Associated Press Finance)
06:57AM	Bausch + Lomb Announces Second-Quarter 2025 Results (Business Wire)
05:38AM	New Strong Sell Stocks for July 30th (Zacks)
Jul-29-25 09:27AM	Bausch & Lomb Corp (TSX:BLCO) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
07:00AM	Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY Preservative Free Redness Reliever Eye Drops (Business Wire)
Jul-28-25 11:09PM	Bausch + Lomb (BLCO) Q2 Earnings Report Preview: What To Look For (StockStory)
Jul-24-25 05:04AM	New Strong Sell Stocks for July 24th (Zacks)
Jul-23-25 10:00AM	Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-22-25 08:45AM	Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity (PR Newswire)
Jul-21-25 09:13AM	Ophthalmic Implants Market: Focused Insights (2025-2030) Featuring Alcon, Carl Zeiss, Bausch + Lomb, Johnson & Johnson and 20 Other Industry Leaders (GlobeNewswire)
Jul-20-25 11:31PM	Medical Devices & Supplies - Specialty Stocks Q1 In Review: Bausch + Lomb (NYSE:BLCO) Vs Peers (StockStory)
Jul-01-25 07:00AM	Bausch + Lomb Combines Patient Voices and New Survey Insights to Combat Persistent Misconceptions about Dry Eye (Business Wire)
Jun-30-25 06:58AM	Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13 (Business Wire)
Jun-26-25 04:30PM	Bausch + Lomb Announces Closing of Upsized 675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility (Business Wire)
Jun-25-25 07:42AM	The Top 5 Analyst Questions From Bausch + Lomb's Q1 Earnings Call (StockStory)
Jun-23-25 11:58AM	Barclays Cut Bausch & Lomb Target to $16, Keeping Rating Neutral in Early June (Insider Monkey)
Jun-18-25 04:30PM	Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering (Business Wire)
Jun-10-25 08:48AM	Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement (Business Wire) +5.01%
Jun-04-25 06:59AM	Bausch + Lomb Launches Blink Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States (Business Wire)
May-27-25 12:47PM	Bausch + Lomb, Organon, Globalstar, Telephone and Data Systems, and nLIGHT Shares Skyrocket, What You Need To Know (StockStory)
May-22-25 07:30AM	Bausch + Lomb to Participate in the 2025 Jefferies Global Healthcare Conference (Business Wire)
12:00AM	3 Reasons to Avoid BLCO and 1 Stock to Buy Instead (StockStory)
May-21-25 04:30PM	Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results (Business Wire)
09:36AM	Anthony Pompliano on taking his SPAC public: Focused on buying a cash-flow positive business (CNBC TV)
06:59AM	Bausch + Lomb Launches New LUMIFY Preservative Free Redness Reliever Eye Drops in the United States (Business Wire)
May-14-25 06:59AM	Bausch + Lomb Launches Zenlens CHROMA HOA in the United States (Business Wire)
May-08-25 12:37AM	3 Profitable Stocks Walking a Fine Line (StockStory)
May-07-25 09:30AM	Bausch + Lomb gets European nod for intraocular lens (Seeking Alpha)
07:00AM	Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife Full Range of Vision Intraocular Lens (Business Wire)
May-01-25 03:08AM	Bausch & Lomb Corp (BLCO) Q1 2025 Earnings Call Highlights: Navigating Growth Amid Challenges (GuruFocus.com)
Apr-30-25 04:40PM	Analyst Report: Bausch + Lomb Corporation (Morningstar Research) -15.74%
11:02AM	Bausch + Lomb Corporation (BLCO) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	Bausch + Lomb (BLCO) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:10AM	Bausch + Lomb (BLCO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:57AM	Bausch + Lomb Announces First-Quarter 2025 Results (Business Wire)
Apr-29-25 03:10AM	Bausch + Lomb (BLCO) Reports Q1: Everything You Need To Know Ahead Of Earnings (StockStory)
Apr-24-25 10:01AM	CVS Health (CVS) Earnings Expected to Grow: Should You Buy? (Zacks) +9.03%
07:00AM	Bausch + Lomb Returning enVista Intraocular Lenses to Market Following Voluntary Recall (Business Wire)

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SAUNDERS BRENT L	CEO and Chairman of the Board	May 22 '25	Buy	11.28	22,000	248,072	719,156	May 27 08:16 AM
VON ESCHENBACH ANDREW C.	Director	May 02 '25	Buy	11.76	1,695	19,925	41,748	May 06 04:30 PM

Open in Screener

SPRY

ARS Pharmaceuticals Inc

Feb 12 • 02:39PM ET

8.91

-0.59 -6.16 %

Healthcare • Biotechnology • USA • NASD

SPRY ARS Pharmaceuticals Inc daily Stock Chart

Peers: ALNY IONS RNA ARWR SRPT NBIX ENTA VRTX RARE ASND

| Held by: VTI XBI IWM VXF IWO IBB VTWO SCHA FYC VHT

Index	RUT	P/E	-	EPS (ttm)	-0.81	Insider Own	38.43%	Shs Outstand	98.84M	Perf Week	-7.81%
Market Cap	881.19M	Forward P/E	-	EPS next Y	-1.38	Insider Trans	-0.79%	Shs Float	60.86M	Perf Month	-21.18%
Enterprise Value	690.74M	PEG	-	EPS next Q	-0.43	Inst Own	65.24%	Short Float	35.16%	Perf Quarter	1.65%
Income	-80.04M	P/S	6.17	EPS this Y	-2247.92%	Inst Trans	1.63%	Short Ratio	12.01	Perf Half Y	-43.65%
Sales	142.77M	P/B	5.97	EPS next Y	19.69%	ROA	-27.11%	Short Interest	21.40M	Perf YTD	-23.48%
Book/sh	1.49	P/C	3.06	EPS next 5Y	-	ROE	-45.92%	52W High	18.90 -52.83%	Perf Year	-23.35%
Cash/sh	2.92	P/FCF	-	EPS past 3/5Y	- -	ROIC	-32.69%	52W Low	6.66 33.85%	Perf 3Y	16.23%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	152.98% -	Gross Margin	89.29%	Volatility	5.51% 5.68%	Perf 5Y	-80.08%
Dividend TTM	-	EV/Sales	4.84	EPS Y/Y TTM	-59.70%	Oper. Margin	-63.59%	ATR (14)	0.62	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.51	Sales Y/Y TTM	5459.66%	Profit Margin	-56.06%	RSI (14)	35.38	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.66	EPS Q/Q	-162.66%	SMA20	-12.21%	Beta	0.77	Target Price	28.33
Payout	0.00%	Debt/Eq	0.66	Sales Q/Q	1471.62%	SMA50	-15.66%	Rel Volume	0.46	Prev Close	9.50
Employees	160	LT Debt/Eq	0.66	Earnings	Nov 10 BMO	SMA200	-28.07%	Avg Volume	1.78M	Price	8.91
IPO	Dec 04, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-14.59% 13.35%	Trades		Volume	663,120	Change	-6.16%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-04-25	Resumed	Roth Capital	Buy	$30
Sep-04-25	Initiated	Roth Capital	Buy	$40
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$30
Feb-10-25	Initiated	Oppenheimer	Outperform	$40
Aug-20-24	Initiated	Cantor Fitzgerald	Overweight
Aug-13-24	Upgrade	Raymond James	Outperform → Strong Buy	$18 → $22
Aug-12-24	Reiterated	Leerink Partners	Outperform	$19 → $20
Jul-25-24	Initiated	Raymond James	Outperform	$18
Mar-05-24	Upgrade	Leerink Partners	Market Perform → Outperform	$6 → $18
Feb-20-24	Upgrade	William Blair	Mkt Perform → Outperform
Sep-20-23	Downgrade	William Blair	Outperform → Mkt Perform
Jan-31-23	Initiated	Wedbush	Outperform	$10
Jan-03-23	Initiated	William Blair	Outperform	$17
Dec-13-22	Initiated	SVB Leerink	Outperform	$14

Show Previous Ratings

Feb-10-26 08:00AM	ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting (GlobeNewswire)
Feb-02-26 01:12PM	What's Going On With Aquestive Therapeutics Stock After FDA Update For Lead Allergic Treatment? (Benzinga)
Jan-21-26 08:00AM	California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use (GlobeNewswire)
Jan-09-26 12:32PM	Bad News For Competitor Turns Into Big Win For ARS Pharma Stock (Benzinga) +19.27%
11:28AM	Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application (Benzinga)
03:16AM	Loading…
03:16AM	ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating (Insider Monkey)
Dec-30-25 08:10AM	ARS Pharmaceuticals announces NMPA approval for neffy 2 mg (TipRanks)
Dec-29-25 08:00AM	neffy (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
Nov-26-25 08:00AM	ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-10-25 04:01PM	ARS Pharmaceuticals Inc (SPRY) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
07:05AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
06:00AM	ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy (epinephrine nasal spray) (GlobeNewswire)
Nov-07-25 07:19AM	ARS Pharmaceuticals Inc (SPRY) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com) +7.99%
Nov-06-25 09:10AM	Lipocine (LPCN) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -9.45%
Nov-05-25 09:15AM	NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
09:35AM	Loading…
Nov-04-25 09:35AM	DraftKings, Flutter downgraded: Wall Street's top analyst calls (The Fly)
08:00AM	ARS Pharma Launches Get neffy on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray) (GlobeNewswire)
Nov-03-25 02:23PM	UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (GlobeNewswire)
08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results (GlobeNewswire)
07:45AM	ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (GlobeNewswire)
Oct-08-25 08:00AM	ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy (epinephrine nasal spray) (GlobeNewswire) +7.55%
Sep-29-25 04:05PM	ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy (GlobeNewswire)
Sep-19-25 08:00AM	neffy (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
Sep-17-25 11:44AM	ARS Pharmaceuticals, Inc. (SPRY): A Bull Case Theory (Insider Monkey)
Sep-09-25 08:11AM	ARS Pharmaceuticals announces real-world evidence on neffy effectiveness (TipRanks)
Sep-08-25 08:00AM	Real-World Evidence Supports Clinical Effectiveness of neffy (epinephrine nasal spray) in Patients Experiencing Anaphylaxis (GlobeNewswire) +6.26%
Sep-04-25 02:54PM	ARS Pharmaceuticals (SPRY) Faces Patent Test as Lupin Files ANDA (Insider Monkey)
Aug-28-25 08:00AM	ARS Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-25 08:15AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -5.04%
07:00AM	ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy (epinephrine nasal spray) (GlobeNewswire)
05:26AM	Loading…
05:26AM	Cisco Systems headlines earnings slate (MarketWatch)
Aug-12-25 09:24AM	ARS Pharmaceuticals Inc (SPRY) Q2 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Aug-11-25 06:55PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -6.40%
Aug-08-25 01:56PM	Paramount, Rocket, and More Stocks See Action From Activist Investors (Barrons.com)
Aug-04-25 08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-31-25 05:35PM	Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates (Zacks)
08:50AM	Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength (Zacks)
Jul-30-25 10:00AM	Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-29-25 10:00AM	Analysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-18-25 12:27PM	MHRA approves needle-free adrenaline nasal spray for anaphylaxis (Pharmaceutical Technology)
09:25AM	EURneffy (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
Jul-15-25 12:00PM	ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy? (Zacks)
09:55AM	Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High? (Zacks)
08:50AM	What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing' (Zacks)
Jun-15-25 05:26AM	Jim Cramer on ARS Pharmaceuticals: "It's a Great Flier" (Insider Monkey)
Jun-11-25 09:02PM	Lightning Round: I don't want to buy enterprise software right now, says Jim Cramer (CNBC TV)
May-27-25 08:00AM	ARS Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-15-25 03:12AM	ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Call Highlights: Strong Launch of Neffy Amid ... (GuruFocus.com)
May-14-25 10:44PM	Q1 2025 ARS Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -9.36%
08:15AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy (epinephrine nasal spray) (GlobeNewswire)
May-13-25 09:28AM	ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
May-08-25 05:06AM	ARS Pharmas epinephrine nasal spray 1mg now available in US (Pharmaceutical Technology)
May-05-25 08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results (GlobeNewswire)
May-04-25 04:32PM	Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential (Seeking Alpha)
May-02-25 08:00AM	ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians (GlobeNewswire)
08:00AM	ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abello A/S to Expand Reach of neffy (epinephrine nasal spray) to Additional U.S. Pediatricians (GlobeNewswire)
Apr-30-25 06:51AM	ARS Pharmaceuticals Has A Blockbuster Candidate (Seeking Alpha)
Apr-05-25 05:31PM	ARS Pharmaceuticals (SPRY): Among Unstoppable Stocks That Could Double Your Money (Insider Monkey)
Mar-23-25 07:18AM	Wall Street Week Ahead (SeekingAlpha)
Mar-21-25 12:16PM	Accenture reports Q2 beat, Apple TV+ losing $1B annually: Morning Buzz (TipRanks) -13.63%
12:03PM	ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
03:03AM	ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
12:40AM	Q4 2024 ARS Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-25 04:04PM	ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why. (Investor's Business Daily) +22.83%
03:31PM	ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await (SeekingAlpha)
01:29PM	ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion (SeekingAlpha)
01:28PM	ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call Transcript (SeekingAlpha)
08:25AM	ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates (Zacks)
07:00AM	ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-06-25 05:27AM	FDA approves ARS neffy 1mg for paediatric anaphylaxis (Pharmaceutical Technology)
Mar-03-25 04:35PM	ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences (GlobeNewswire)
Feb-20-25 07:02PM	ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients (GlobeNewswire)
Feb-18-25 08:00AM	ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting (GlobeNewswire)
Feb-05-25 08:00AM	ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference (GlobeNewswire)
Jan-21-25 08:00AM	ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools (GlobeNewswire) +7.24%
Jan-13-25 04:15PM	BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. (Investor's Business Daily)
08:00AM	ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy (epinephrine nasal spray) (GlobeNewswire)
Jan-07-25 08:15AM	ARS Pharmaceuticals files for approval of neffy in Canada, U.K. (TipRanks)
06:43AM	ARS Pharma seeks approval for epinephrine spray in Canada and UK (Medical Device Network)
Jan-06-25 08:00AM	ARS Pharmaceuticals Files for Approval of neffy in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abello A/S (GlobeNewswire)
08:00AM	ARS Pharmaceuticals Files for Approval of neffy in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abell A/S (GlobeNewswire)
Dec-19-24 05:25PM	ARS Pharmaceuticals Announces neffy (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies (GlobeNewswire)
Dec-18-24 08:00AM	ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.80%
Dec-12-24 02:32PM	ARS Pharmaceuticals Announces Filings for Approval of neffy in China, Japan and Australia (GlobeNewswire)
Dec-04-24 08:00AM	ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost (GlobeNewswire) +5.95%
Nov-14-24 02:08AM	ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ... (GuruFocus.com)
Nov-13-24 07:40AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -15.23%
06:30AM	ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-12-24 07:06AM	ARS Pharmaceuticals announces agreement with ALK to commercialize neffy (TipRanks) -5.03%
Nov-11-24 04:02PM	ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray (Investor's Business Daily)
11:01AM	ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m (Pharmaceutical Technology)
07:41AM	ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 (Benzinga)
07:00AM	ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy in Europe, Canada and Other Geographies Outside the United States (GlobeNewswire)
Nov-09-24 05:30PM	ALK licenses rights to neffy , the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) (GlobeNewswire)
Nov-06-24 09:55AM	Wall Street Analysts Think ARS Pharmaceuticals, Inc. (SPRY) Could Surge 67.56%: Read This Before Placing a Bet (Zacks)
08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences (GlobeNewswire)
Oct-24-24 08:30AM	ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (GlobeNewswire)
Oct-14-24 09:55AM	Wall Street Analysts Believe ARS Pharmaceuticals, Inc. (SPRY) Could Rally 76.79%: Here's is How to Trade (Zacks)
Sep-30-24 10:33AM	Neffy nasal spray: a game changer for asthma patients and epinephrine delivery? (Pharmaceutical Technology)

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dorsey Brian	Chief Operating Officer	Nov 13 '25	Option Exercise	0.64	21,828	13,970	32,617	Nov 14 06:43 PM
Dorsey Brian	Chief Operating Officer	Nov 13 '25	Sale	8.71	21,828	190,050	10,789	Nov 14 06:43 PM
Chakma Justin	Chief Business Officer	Nov 12 '25	Option Exercise	0.84	30,000	25,200	166,380	Nov 14 06:42 PM
Chakma Justin	Chief Business Officer	Nov 12 '25	Sale	8.87	166,380	1,476,147	0	Nov 14 06:42 PM
BRIAN T DORSEY	Officer	Nov 13 '25	Proposed Sale	8.71	21,828	190,050		Nov 13 04:08 PM
JUSTIN CHAKMA	Officer	Nov 12 '25	Proposed Sale	8.91	30,000	267,357		Nov 12 05:26 PM
Chakma Justin	Officer	Nov 12 '25	Proposed Sale	8.87	138,380	1,227,420		Nov 12 10:56 AM
Lowenthal Richard E	PRESIDENT AND CEO	Aug 21 '25	Sale	14.49	50,000	724,345	1,196,494	Aug 22 04:30 PM
Scott Kathleen D.	Chief Financial Officer	Aug 21 '25	Option Exercise	1.50	12,500	18,750	22,542	Aug 22 04:30 PM
Scott Kathleen D.	Chief Financial Officer	Aug 21 '25	Sale	15.00	12,500	187,500	10,042	Aug 22 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Aug 20 '25	Sale	14.09	37,656	530,626	1,247,447	Aug 21 05:36 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Aug 19 '25	Sale	14.03	12,344	173,130	1,285,103	Aug 21 05:36 PM
KATHLEEN D SCOTT	Officer	Aug 21 '25	Proposed Sale	15.00	12,500	187,500		Aug 21 04:18 PM
Lowenthal Richard E	Officer	Aug 21 '25	Proposed Sale	14.15	150,000	2,123,000		Aug 21 11:20 AM
Tanimoto Sarina	Officer	Aug 19 '25	Proposed Sale	14.00	150,000	2,100,000		Aug 19 10:22 AM
Karas Eric	Chief Commercial Officer	Jul 01 '25	Option Exercise	1.50	15,000	22,500	25,315	Jul 03 04:21 PM
Karas Eric	Chief Commercial Officer	Jul 01 '25	Sale	16.99	15,000	254,860	10,315	Jul 03 04:21 PM
Flynn James E	10% Owner	Jun 27 '25	Sale	18.46	740,149	13,663,151	4,887,254	Jul 01 04:42 PM
ERIC KARAS	Officer	Jul 01 '25	Proposed Sale	16.99	15,000	254,859		Jul 01 04:20 PM
Karas Eric	Chief Commercial Officer	Jun 18 '25	Option Exercise	1.50	15,000	22,500	22,696	Jun 20 06:38 PM
Karas Eric	Chief Commercial Officer	Jun 18 '25	Sale	16.00	15,000	240,000	7,696	Jun 20 06:38 PM
ERIC KARAS	Officer	Jun 18 '25	Proposed Sale	16.00	15,000	240,000		Jun 18 04:51 PM
Fitzpatrick Alexander A	Chief Legal Officer	May 20 '25	Option Exercise	5.58	100,000	558,000	192,582	May 22 05:00 PM
Fitzpatrick Alexander A	Chief Legal Officer	May 20 '25	Sale	14.10	102,969	1,451,513	89,613	May 22 05:00 PM
SAUNDERS BRENT L	Director	May 20 '25	Option Exercise	1.01	120,000	121,200	120,000	May 22 05:00 PM
SAUNDERS BRENT L	Director	May 20 '25	Sale	14.25	120,000	1,710,024	0	May 22 05:00 PM
Scott Kathleen D.	Chief Financial Officer	May 20 '25	Option Exercise	1.50	50,000	75,000	57,424	May 22 05:00 PM
Scott Kathleen D.	Chief Financial Officer	May 20 '25	Sale	14.10	50,000	705,165	7,424	May 22 05:00 PM
Scott Kathleen D.	Officer	May 20 '25	Proposed Sale	14.10	50,000	705,000		May 20 05:24 PM
Fitzpatrick Alexander A	Officer	May 20 '25	Proposed Sale	14.02	102,969	1,443,894		May 20 04:50 PM
SAUNDERS BRENT L	Director	May 20 '25	Proposed Sale	14.25	120,000	1,710,000		May 20 04:48 PM
Shawver Laura	Director	Apr 07 '25	Option Exercise	4.85	50,002	242,510	260,348	Apr 08 04:45 PM
Shawver Laura	Director	Apr 07 '25	Sale	12.30	50,002	615,075	210,346	Apr 08 04:45 PM
Shawver Laura	Director	Apr 07 '25	Proposed Sale	12.30	50,002	615,051		Apr 07 02:26 PM
Karas Eric	Chief Commercial Officer	Mar 20 '25	Option Exercise	1.50	10,000	15,000	17,696	Mar 21 06:30 PM
Karas Eric	Chief Commercial Officer	Mar 20 '25	Sale	14.00	10,000	140,000	7,696	Mar 21 06:30 PM
ERIC KARAS	Officer	Mar 20 '25	Proposed Sale	14.00	10,000	140,000		Mar 20 04:03 PM
Shawver Laura	Director	Mar 06 '25	Option Exercise	4.85	49,600	240,560	259,946	Mar 07 05:12 PM
Shawver Laura	Director	Mar 05 '25	Option Exercise	4.85	400	1,940	210,746	Mar 07 05:12 PM
Shawver Laura	Director	Mar 06 '25	Sale	11.21	49,600	556,046	210,346	Mar 07 05:12 PM
Shawver Laura	Director	Mar 05 '25	Sale	11.00	400	4,400	210,346	Mar 07 05:12 PM
Shawver Laura	Director	Mar 05 '25	Proposed Sale	11.00	50,000	550,000		Mar 05 05:19 PM

SKIN Beauty Health Company daily Stock Chart

Peers: EL ULTA COTY LB SBH NUS VRME IRWD VICI EPC

| Held by: VTI IWM VDC VXF IWO VTWO SCHA IWC JSML IWN

Index	RUT	P/E	-	EPS (ttm)	-0.22	Insider Own	39.47%	Shs Outstand	127.30M	Perf Week	-18.22%
Market Cap	134.51M	Forward P/E	-	EPS next Y	-0.13	Insider Trans	0.00%	Shs Float	77.18M	Perf Month	-31.05%
Enterprise Value	294.09M	PEG	-	EPS next Q	-0.05	Inst Own	64.98%	Short Float	20.79%	Perf Quarter	-19.47%
Income	-11.74M	P/S	0.45	EPS this Y	69.24%	Inst Trans	3.97%	Short Ratio	27.52	Perf Half Y	-55.67%
Sales	301.92M	P/B	2.05	EPS next Y	-81.81%	ROA	-1.95%	Short Interest	16.05M	Perf YTD	-24.10%
Book/sh	0.52	P/C	0.61	EPS next 5Y	8.28%	ROE	-18.73%	52W High	2.69 -60.78%	Perf Year	-34.88%
Cash/sh	1.72	P/FCF	3.49	EPS past 3/5Y	53.75% -48.09%	ROIC	-2.67%	52W Low	0.78 35.26%	Perf 3Y	-91.31%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	8.73% 14.94%	Gross Margin	64.81%	Volatility	9.31% 5.74%	Perf 5Y	-90.72%
Dividend TTM	-	EV/Sales	0.97	EPS Y/Y TTM	57.98%	Oper. Margin	-9.31%	ATR (14)	0.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.07	Sales Y/Y TTM	-13.14%	Profit Margin	-3.89%	RSI (14)	22.71	Recom	3.22
Dividend Gr. 3/5Y	- -	Current Ratio	4.98	EPS Q/Q	41.04%	SMA20	-24.92%	Beta	1.18	Target Price	1.96
Payout	-	Debt/Eq	5.77	Sales Q/Q	-10.34%	SMA50	-27.01%	Rel Volume	0.54	Prev Close	1.06
Employees	769	LT Debt/Eq	5.70	Earnings	Nov 06 AMC	SMA200	-36.31%	Avg Volume	583.01K	Price	1.05
IPO	Nov 24, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-21.79% 3.14%	Trades		Volume	251,114	Change	-0.47%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-19-25	Initiated	Roth Capital	Buy	$3.50
Nov-15-23	Downgrade	Jefferies	Buy → Hold	$11 → $1.50
Nov-14-23	Downgrade	William Blair	Outperform → Mkt Perform
Nov-14-23	Downgrade	The Benchmark Company	Buy → Hold
Nov-14-23	Downgrade	TD Cowen	Outperform → Market Perform	$9 → $2.50
Nov-14-23	Downgrade	Raymond James	Mkt Perform → Underperform
Nov-14-23	Downgrade	Piper Sandler	Overweight → Underweight	$12 → $2
Nov-14-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-14-23	Downgrade	Canaccord Genuity	Buy → Hold	$10 → $2.50
Aug-25-23	Resumed	Canaccord Genuity	Buy	$10
Jun-21-23	Downgrade	Stifel	Buy → Hold	$17 → $10
Mar-20-23	Upgrade	Exane BNP Paribas	Underperform → Neutral
Nov-09-22	Downgrade	JP Morgan	Overweight → Neutral	$22 → $11
Mar-11-22	Initiated	JP Morgan	Overweight	$24
Jan-07-22	Initiated	William Blair	Outperform
Dec-23-21	Initiated	Raymond James	Mkt Perform
Oct-08-21	Initiated	Stifel	Buy	$33
Oct-04-21	Initiated	Cowen	Outperform	$32
Jul-19-21	Initiated	Jefferies	Buy	$22
Jul-01-21	Initiated	Goldman	Buy	$31

Show Previous Ratings

Jan-25-26 11:34PM	1 Russell 2000 Stock Worth Your Attention and 2 We Brush Off (StockStory)
Jan-01-26 11:40PM	3 Volatile Stocks That Fall Short (StockStory)
Dec-08-25 11:36PM	3 of Wall Street's Favorite Stocks with Warning Signs (StockStory)
Dec-05-25 03:15PM	HALPER SADEH LLC ENCOURAGES THE BEAUTY HEALTH COMPANY SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire) -7.59%
Dec-04-25 09:15AM	BeautyHealth Releases Third Annual Skintuition Report (GlobeNewswire)
11:34PM	Loading…
Dec-03-25 11:34PM	1 Small-Cap Stock with Impressive Fundamentals and 2 We Turn Down (StockStory) +9.66%
Nov-30-25 03:07PM	HALPER SADEH LLC ENCOURAGES THE BEAUTY HEALTH COMPANY SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
Nov-17-25 09:15AM	Unlocking Beauty Health (SKIN) International Revenues: Trends, Surprises, and Prospects (Zacks)
Nov-16-25 10:34PM	Personal Care Stocks Q3 Recap: Benchmarking BeautyHealth (NASDAQ:SKIN) (StockStory)
Nov-13-25 12:37AM	5 Revealing Analyst Questions From BeautyHealth's Q3 Earnings Call (StockStory)
Nov-07-25 01:10PM	Why BeautyHealth (SKIN) Stock Is Up Today (StockStory) +8.53%
09:27AM	SKIN Q3 Deep Dive: Margin Expansion and Strategic Refocus Amid Device Market Headwinds (StockStory)
Nov-06-25 06:00PM	Here's What Key Metrics Tell Us About Beauty Health (SKIN) Q3 Earnings (Zacks) -12.24%
05:40PM	The Beauty Health Company (SKIN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:13PM	BeautyHealth (NASDAQ:SKIN) Beats Q3 Sales Expectations, Stock Jumps 16.7% (StockStory)
04:05PM	Loading…
04:05PM	BeautyHealth Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-04-25 10:09PM	Earnings To Watch: BeautyHealth (SKIN) Reports Q3 Results Tomorrow (StockStory) +6.52%
Nov-03-25 04:05PM	BeautyHealth Appoints Philippe Schaison, PharmaD, to Board of Directors (GlobeNewswire)
01:20PM	Why BeautyHealth (SKIN) Shares Are Falling Today (StockStory)
Oct-27-25 08:00AM	Halper Sadeh LLC Encourages The Beauty Health Company Shareholders to Contact the Firm to Discuss Their Rights (Business Wire) +5.04%
Oct-24-25 08:15AM	HCA Healthcare (HCA) Q3 Earnings and Revenues Top Estimates (Zacks) +6.92%
12:35AM	1 Russell 2000 Stock Worth Your Attention and 2 We Avoid (StockStory)
Oct-23-25 10:00AM	BeautyHealth to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-22-25 11:32PM	Personal Care Q2 Earnings: BeautyHealth (NASDAQ:SKIN) Simply the Best (StockStory)
Oct-14-25 12:32AM	3 of Wall Street's Favorite Stocks We Find Risky (StockStory)
Sep-30-25 04:30PM	The Beauty Health Company Names Pedro Malha President and Chief Executive Officer (GlobeNewswire) -10.80%
12:33AM	3 Unprofitable Stocks with Open Questions (StockStory)
Sep-28-25 07:19PM	The Beauty Health Company (SKIN) Smashes Q2 Expectations With Surprise Profit, $78.2M Revenue (Insider Monkey)
Sep-23-25 03:25PM	Why BeautyHealth (SKIN) Stock Is Nosediving (StockStory)
08:00AM	Hydrafacial Joins Cosmopolitan Readers' Choice Hall of Fame as Three-Time Winner for Best Pro Facial (GlobeNewswire)
12:38AM	Loading…
Sep-11-25 12:38AM	1 Cash-Producing Stock to Target This Week and 2 Facing Challenges (StockStory) +7.39%
Sep-10-25 12:01PM	Why BeautyHealth (SKIN) Stock Is Trading Lower Today (StockStory) -5.74%
Sep-09-25 09:38AM	MULTIMEDIA UPDATE -- Hydrafacial Launches Inaugural Hydrafacial Advisory Councils & Ambassador Network to Fuel Next-Era Innovation and Growth (GlobeNewswire)
08:00AM	Hydrafacial Launches Inaugural Hydrafacial Advisory Councils & Ambassador Network to Fuel Next-Era Innovation and Growth (GlobeNewswire)
Sep-08-25 03:36PM	BeautyHealth (SKIN) Shares Skyrocket, What You Need To Know (StockStory) +13.66%
Sep-01-25 12:00AM	3 Reasons SKIN is Risky and 1 Stock to Buy Instead (StockStory)
Aug-21-25 02:55PM	BeautyHealth, Polaris, Herc, Quanex, and Vestis Shares Are Falling, What You Need To Know (StockStory)
Aug-14-25 01:33AM	The 5 Most Interesting Analyst Questions From BeautyHealth's Q2 Earnings Call (StockStory) -8.82%
Aug-12-25 01:50PM	Why BeautyHealth (SKIN) Stock Is Up Today (StockStory)
08:50AM	Fast-paced Momentum Stock Beauty Health (SKIN) Is Still Trading at a Bargain (Zacks)
Aug-11-25 09:40AM	SKIN Q2 Deep Dive: Recurring Consumables Revenue, Margin Expansion, and Strategic Product Initiatives (StockStory) +16.93%
09:15AM	International Markets and Beauty Health (SKIN): A Deep Dive for Investors (Zacks)
Aug-08-25 12:20PM	Why BeautyHealth (SKIN) Stock Is Up Today (StockStory) +18.87%
Aug-07-25 07:30PM	Beauty Health (SKIN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:00PM	The Beauty Health Company (SKIN) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
05:49PM	BeautyHealth (NASDAQ:SKIN) Delivers Impressive Q2, Stock Jumps 18.7% (StockStory)
04:05PM	BeautyHealth Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-06-25 07:40AM	Cencora (COR) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Aug-05-25 11:10PM	BeautyHealth (SKIN) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Jul-31-25 10:00AM	The Beauty Health Company (SKIN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-28-25 07:10AM	Revvity (RVTY) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
Jul-24-25 10:00AM	BeautyHealth to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire) -9.41%
08:50AM	Why Fast-paced Mover Beauty Health (SKIN) Is a Great Choice for Value Investors (Zacks)
Jul-21-25 12:31AM	3 Cash-Producing Stocks That Concern Us (StockStory)
Jul-01-25 08:50AM	Despite Fast-paced Momentum, Beauty Health (SKIN) Is Still a Bargain Stock (Zacks) +13.09%
Jun-30-25 06:31AM	5 Revealing Analyst Questions From BeautyHealth's Q1 Earnings Call (StockStory)
Jun-23-25 11:35PM	Personal Care Stocks Q1 In Review: BeautyHealth (NASDAQ:SKIN) Vs Peers (StockStory) +19.88%
Jun-10-25 08:00AM	Hydrafacial Unveils New HydraFillic with Pep9 Skin Booster For Fine Line & Wrinkles (GlobeNewswire)
05:30AM	SKIN Q1 Earnings Call: Consumables Growth, Equipment Headwinds, and Tariff Impact Shape Outlook (StockStory)
12:03AM	3 Reasons to Avoid SKIN and 1 Stock to Buy Instead (StockStory)
Jun-04-25 08:00AM	BeautyHealth Surpasses 35,000 Hydrafacial Devices Worldwide Reflecting Growing Consumer Demand for Clinically Proven Skin Health Treatments (GlobeNewswire)
May-21-25 08:00AM	The Beauty Health Company Announces Convertible Debt Refinancing (GlobeNewswire) -7.69%
May-13-25 09:16AM	Beauty Health (SKIN) Reliance on International Sales: What Investors Need to Know (Zacks) -16.48%
May-09-25 03:43AM	The Beauty Health Co (SKIN) Q1 2025 Earnings Call Highlights: Surpassing Revenue Expectations ... (GuruFocus.com) +50.81%
May-08-25 07:30PM	Beauty Health (SKIN) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks) -12.68%
06:05PM	The Beauty Health Company (SKIN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	BeautyHealth Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 05:35PM	The Beauty Health Q1 2025 Earnings Preview (Seeking Alpha) +35.24%
11:27AM	What To Expect From The Beauty Health Co (SKIN) Q1 2025 Earnings (GuruFocus.com)
May-05-25 12:42AM	3 Volatile Stocks Walking a Fine Line (StockStory) -7.02%
May-02-25 07:15AM	BrightSpring Health Services, Inc. (BTSG) Q1 Earnings and Revenues Beat Estimates (Zacks) +10.68%
Apr-29-25 04:00PM	BeautyHealth to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-23-25 05:01AM	3 Reasons to Avoid SKIN and 1 Stock to Buy Instead (StockStory) +6.29%
Apr-05-25 09:49AM	3 Small-Cap Stocks with Mounting Challenges (StockStory)
Mar-18-25 05:07AM	Unpacking Q4 Earnings: BeautyHealth (NASDAQ:SKIN) In The Context Of Other Personal Care Stocks (StockStory)
Mar-13-25 03:08AM	The Beauty Health Co (SKIN) Q4 2024 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com) -5.63%
Mar-12-25 04:05PM	BeautyHealth Reports Full Year and Fourth Quarter 2024 Financial Results (GlobeNewswire)
Mar-04-25 04:05PM	BeautyHealth to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025 (GlobeNewswire) -9.02% +11.21%
Dec-17-24 04:30PM	BeautyHealth Appoints Stephen J. Fanning to Board of Directors (Business Wire) -12.42%
Dec-11-24 08:00AM	BeautyHealth Releases 2024 Skintuition Report (Business Wire)
Nov-13-24 02:18AM	The Beauty Health Co (SKIN) Q3 2024 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com) +8.82%
Nov-12-24 04:05PM	BeautyHealth Reports Third Quarter 2024 Financial Results (Business Wire)
Nov-08-24 08:00AM	BeautyHealth to Report Third Quarter 2024 Financial Results on November 12, 2024 (Business Wire)
Oct-17-24 03:28PM	Hydrafacial Announces Video Poster Abstract Presentation at the 2024 American Society for Dermatologic Surgerys Annual Meeting (ASDS): Hydrafacial enhances the outcomes of non-ablative laser and IPL treatments (Business Wire)
Oct-15-24 04:10PM	The Beauty Health Company Strengthens Commercial Leadership Team with Chief Revenue Officer and Chief Marketing Officer Appointments (Business Wire)
10:51AM	Hydrafacial Announces Glow Getter Scholarship Program in Support of Estheticians (Business Wire)
Oct-01-24 08:00AM	Hydrafacial Launches New Hydralock HA Booster with Clinically Proven Results (Business Wire)
Aug-08-24 04:35PM	BeautyHealth (NASDAQ:SKIN) Reports Sales Below Analyst Estimates In Q2 Earnings, Stock Drops 22.5% (StockStory) -13.18%
04:05PM	BeautyHealth Reports Second Quarter 2024 Financial Results (Business Wire)
Jul-30-24 08:00AM	BeautyHealth to Report Second Quarter 2024 Financial Results on August 8, 2024 (Business Wire)
May-10-24 12:45PM	The Beauty Health Company (NASDAQ:SKIN) Q1 2024 Earnings Call Transcript (Insider Monkey) -23.68%
May-09-24 06:30PM	Here's What Key Metrics Tell Us About Beauty Health (SKIN) Q1 Earnings (Zacks)
06:10PM	The Beauty Health Company (SKIN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:40PM	BeautyHealth (NASDAQ:SKIN) Beats Q1 Sales Targets But Quarterly Guidance Underwhelms (StockStory)
04:05PM	BeautyHealth Reports First Quarter 2024 Financial Results (Business Wire)
Apr-26-24 08:00AM	BeautyHealth to Report First Quarter 2024 Financial Results on May 9, 2024 (Business Wire) +5.88%
Apr-09-24 04:10PM	BeautyHealth Names Sheri Lewis as Chief Supply Chain and Operations Officer (Business Wire)
Mar-28-24 01:38PM	15 Best Beauty Stocks To Invest In (Insider Monkey)
04:45AM	Should You Sell The Beauty Health Company (SKIN)? (Insider Monkey)
Mar-13-24 09:02AM	The Beauty Health Company (NASDAQ:SKIN) Q4 2023 Earnings Call Transcript (Insider Monkey) +18.38%

The Beauty Health Co. engages in the design, development, manufacture, marketing, and sale of esthetic technologies and products. Its brands include Hydrafacial, SkinStylus, and Keravive. The company was founded in 1997 and is headquartered in Long Beach, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BECK MARLA MALCOLM	Former Officer & Director	Dec 05 '25	Proposed Sale	1.61	5,000	8,074		Dec 05 01:04 PM
Paul Bokota	General Counsel	Jun 06 '25	Proposed Sale	1.60	12,000	19,200		Jul 01 04:05 PM

BLCO

Bausch + Lomb Corp

SPRY

ARS Pharmaceuticals Inc

SKIN

Beauty Health Company

Upgrade your FINVIZ experience